Clinical trial
Long-term Safety of Gamifant® in Adult and Pediatric Patients With HLH/MAS in Still's Disease With Inadequate Response or Intolerance to Glucocorticoids, or With Recurrent MAS
NCT07909005 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term Safety of Gamifant® in Adult and Pediatric Patients With HLH/MAS in Still's Disease With Inadequate Response or Intolerance to Glucocorticoids, or With Recurrent MAS
- Lead sponsor
- Swedish Orphan Biovitrum
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- December 31, 2030
- Enrollment
- 70 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
hemophagocytic lymphohistiocytosis (hlh), macrophage activation syndrome (mas), still disease
Arms
As registered; 1 arm.
-
HLH/MAS in Still's disease treated with Gamifant
Patients aged ≤80 years at index Gamifant administration who have received at least 1 dose of Gamifant 0-7 days prior to ICF date or is prescribed to initiate Gamifant for the treatment of HLH/MAS in Still's disease
Primary endpoints
Registered primary outcome measures; 4 primary.
-
Outcome Measure: Incidence rate of treatment-emergent mycobacterium tuberculosis
Description: Occurrence of treatment-emergent mycobacterium tuberculosis and non-tuberculosis mycobacterium. A TEAE is defined as any AE that occurs from the administration of the index dose of Gamifant until the initial 12 months of follow-up, regardless of relationship to Gamifant.
Unit of Measure: Number of events per 100-patient year
-
Outcome Measure: Incidence rate of treatment-emergent non-tuberculosis mycobacterium infections
Description: Occurrence of treatment-emergent mycobacterium tuberculosis and non-tuberculosis mycobacterium. A TEAE is defined as any AE that occurs from the administration of the index dose of Gamifant until the initial 12 months of follow-up, regardless of relationship to Gamifant.
Unit of Measure: Unit of Measure: Number of events per 100-patient year
-
Outcome Measure: Incidence rate of treatment-emergent CMV reactivation and/or infection
Description: Occurrence of treatment-emergent CMV disease including reactivation and/or infection. A TEAE is defined as any AE that occurs from the administration of the index dose of Gamifant until the initial 12 months of follow-up, regardless of relationship to Gamifant.
Unit of Measure: Number of events per 100-patient year
-
Outcome Measure: Incidence rate of serious treatment-emergent infections
Description: Occurrence of serious treatment-emergent infections (including CMV reactivation and/or infection, mycobacterium tuberculosis, and non tuberculosis mycobacterial infections). A TEAE is defined as any AE that occurs from the administration of the index dose of Gamifant until the initial 12 months of follow-up, regardless of relationship to Gamifant.
Unit of Measure: Number of events per 100-patient year
Lead sponsor's other trials
Swedish Orphan Biovitrum, most recent start first.
+76 more trials See the organization page
Similar trials
Same condition (Macrophage Activation Syndrome) and phase, most recent start first.
+3 more trials See the condition page